Bain Capital Life Sciences — Full Portfolio

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Board seatAndrew Hack· per SEC Form D

Co-investorsBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+4 more

BiotechCambridge, US

Joshua Cohen(Executive Officer, Director)inJustin Klee(Director)in

BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)

BiotechWestlake Village, US

Alexander Asam(Director)Ricky Sun(Director)Todd Franklin Watanabe(Executive Officer, Director)

BoardPatrick Heron(Director)inDaniel Estes(Director)inJonathan Silverstein(Director)

Co-investorsRA CapitalFrazier Life Sciences

Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).

BiotechHealthtechBoston, US

Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)

BoardBruno Lucidi(Director)Evgeny Zatsev(Director)Frank Yu(Director)Gerald Chan(Director)Bruce Polsky(Director)

Co-investorsRA Capital

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

BoardMarc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)Bihua Chen(Director)William M. Scalzulli(Director)

Co-investors3E Bioventures CapitalNextech InvestRA Capital

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess BiotechnologyAtlas VentureForesite CapitalFrazier Life SciencesOrbiMed5AM Ventures+6 more

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGabriel Otte(Director)in

BoardStuart Lawson(Director)

Co-investorsRA CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+8 more

Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD).

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesRedwood City, US

Christopher K. Zarins(Executive Officer, Director)inCharles A. Taylor(Executive Officer, Director)inNicky Espinosa Hayes(Executive Officer)John Stevens(Executive Officer, Director)inH. Baird Radford, III(Executive Officer)John Farquharin

Co-investorsBlue Venture FundsEmergent Medical Partners, LLPKhosla VenturesLifeforce CapitalLotus CapitalSilver Lake Partners+1 more

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsForesite CapitalMRL Ventures FundPremji InvestMithril Capital Management

Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions designed for collaborative care between providers and patients.

Digital HealthHardwareHealthtechMedical Devices

Co-investorsAndera PartnersLongitude Capital

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in

Co-investorsAtlas VentureAvoro Capital AdvisorsBessemer Venture PartnersHatteras Venture PartnersMRL Ventures FundNextech Invest+3 more

BiotechEmeryville, US

Brian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)James Chung(Executive Officer)

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)in

Co-investorsCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersLightspeed Venture PartnersRA Capital+1 more

Co-investorsForesite Capital

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)in

BoardLaurence Lasky(Director)Alexis Borisy(Director)Elizabeth Anderson(Director)Michael Bonney(Director)

Co-investorsForesite CapitalNextech InvestThird Rock Ventures

Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases.

BiotechHealthtechMedical DevicesAustin, US

Matt Pauls(Chair of the Board of Directors and Chief Executive Officer)inMike Ciesla(Executive Officer)Badrul Chowdhury(Executive Officer)inSantosh J. Vetticaden(Executive Officer)Gregory D. Gorgas(Executive Officer)Patrick Keran(Executive Officer)

Co-investorsCentral Texas Angel NetworkGreen Park & Golf VenturesKeiretsu ForumMoore Venture PartnersNew Enterprise Associates (NEA)

Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.

BiotechHealthtechMedical Devices

Bobak Azamian, MD, PhD(Founder)in

Co-investorsAPERTURE Venture PartnersFlying L PartnersFrazier Life SciencesVisionary VenturesVivo CapitalRTW Investments L.P.

Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.

BiotechHealthtechWaltham, US

Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in

Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyDecheng CapitalSamsara BioCapitalTCG Crossover+1 more

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham VenturesREDMILE+8 more

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical Devices

Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in

Co-investorsOrbiMedLilly Asia VenturesSR One Capital ManagementT. Rowe PriceTCG CrossoverVivo Capital

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)Michael Naill(Senior Vice President, Process and Product Development)in

Co-investorsThird Rock VenturesBiotechnology Value FundGV (Google Ventures)

Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.

BiotechHealthtechMedical DevicesBaar, CH

Co-investorsHBM PartnersMérieux Equity PartnersSK Capital Partners

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Board seatAdam M. Koppel· per SEC Form D

Co-investorsFrazier Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)Agent CapitalHBM Healthcare Investments+2 more

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

BiotechChapel Hill, US

Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)Jorge Bartolome(Executive Officer, Director)

BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)

Board seatAdam M. Koppel· per SEC Form D

Co-investorsARCH Venture PartnersGV (Google Ventures)Access BiotechnologyMaverick CapitalSaturn PartnersViking Global Investors

BiotechBurlington, US

Michael Mendelsohn(Executive Officer, Director)

BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Edward Mathers(Director)Adam Koppel(Director)in

Board seatNicholas DowningAdam M. Koppel· per SEC Form D

Co-investorsBain CapitalBain Capital Tech OpportunitiesNEA SecondaryPolaris PartnersThird Rock Ventures

JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis.

Digital HealthHealthtechMedical DevicesIrvine, US

Hans Figulla(Director)Markus FerrariVictoria Carr-Brendel(Executive Officer, Director)David Drachman(Executive Officer, Director)

BoardArnd Kaltofen(Director)inErik Amble(Director)

Board seatAndrew Hack· per SEC Form D

Co-investorsAndera PartnersVI PartnersGimvInnovatus Capital PartnersLegend Capital

A Place for Mom is a U.S. and Canadian senior care referral marketplace connecting families with senior living and home care providers.

Vernon Hills, US

Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)Neal Campbell(Executive Officer)Christina Rother(Executive Officer)

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBlue Sea CapitalClayton Dubilier & RiceCore Venture CapitalDFJ+11 more

Co-investorsSR One Capital Management

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAbingworthAlly Bridge Group+2 more

Affera develops a medical technology platform for treating cardiac arrhythmias, including atrial fibrillation, using innovative ablation solutions.

HealthtechMedical DevicesNewton, US

Doron Harlev(CEO, Founder)in

Co-investorsElysia Capital

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsEcoR1 CapitalForesite CapitalBain CapitalRock Springs CapitalT. Rowe Price

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsRA CapitalSofinnova Ventures

Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Carlos Quezada-Ruiz(Chief Medical Officer)in

Co-investorsSofinnova VenturesTCG Crossover

Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.

BiotechHealthtechSo. San Francisco, US

Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)Thomas Wiggans(Director)Ricky Sun(Director)

Co-investorsCorrelation VenturesNew Enterprise Associates (NEA)Clarus

Bain Capital is a private investment firm founded in 1984 that invests in and partners with companies to drive growth and improvement.

Sector AgnosticBoston, US

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBCIGentree Fund

Bain Capital Credit is an investment firm specializing in credit strategies including liquid and structured credit, leveraged loans, high-yield bonds, CLOs, and direct lending to middle-market companies.

Fintech

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Bain Capital Private Equity is an investment firm operating a private equity portfolio, with an investor portal for account holders.

Boston, US

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Bain Capital Special Situations is a private investment firm that combines private equity, private credit, and asset-backed capital to source and structure specialized deals across asset classes.

FintechSector AgnosticHong Kong, HK

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Bain Capital Double Impact is an investment firm established in 2015 that funds companies generating both competitive financial returns and measurable social or environmental impact, with focus areas spanning healthcare access, economic opportunity, and environmental sustainability.

EdTechHealthtechImpact & Social Good

Co-investorsBain Capital Tech OpportunitiesBain Capital VentureBlue Haven Initiative

Bain Capital Real Estate is an investment firm focused on acquiring and operating real estate assets in niche, difficult-to-access sectors driven by long-term economic and secular trends.

PropTechBoston, US

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Beeline provides vendor management system (VMS) software for managing contingent and external workforces, including staffing suppliers and shift-based labor.

Future of WorkHR TechSaaS

Co-investorsAcadian Ventures Management, Llc

Beeline Medicines is a biopharmaceutical company developing medicines for patients with serious diseases.

BiotechHealthtechMedical DevicesStamford, US

Dr. Badreddin Edris(President and Chief Operating Officer)Saqib Islam(Chief Executive Officer)inNathalie Franchimont(Chief Medical Officer)in

Co-investorsBain Capital

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)

Co-investorsAtlas VentureJanus Henderson InvestorsLAVOmega FundsvenBio Global StrategicvenBio Partners+1 more

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

Michael E. Mendelsohn(Founder and Chief Strategy Officer)inMichael Mendelsohn, M.D.(Founder)in

Co-investorsBain CapitalDelos CapitalDigitalis VenturesNew Enterprise Associates (NEA)Ascenta CapitalBain Capital Tech Opportunities+4 more

CereVasc is developing the eShunt System, a minimally invasive device intended to treat communicating hydrocephalus in children and adults as an alternative to invasive neurosurgical procedures.

BiotechHealthtechMedical DevicesAuburndale, US

Carl Heilman(Director)Daniel Levangie(Executive Officer, Director)inLeslie Teso-Lichtman(Executive Officer)inFrederick Callori(Director)Patrick Sullivan(Director)Aaron Levangie(Executive Officer)

Co-investorsFrazier Life Sciences

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in

Co-investors5AM VenturesAisling CapitalFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more

BiotechCambridge, US

Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)

BoardMartin Murphy(Director)

Co-investorsCasdin CapitalLifeSci Venture PartnersVenrock Healthcare Capital Partners

BiotechHealthtechCambridge, US

Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)

Co-investorsAvoro Capital AdvisorsVenrockThe Column GroupThird Rock Ventures

A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.

BiotechDigital HealthHealthtech

Co-investorsAccess Biotechnology

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome.

BiotechMedical Devices

Co-investorsParagon Biosciences LLCFidelity InvestmentsValor Equity Partners

Global company developing next-generation eye disease therapies; acquired by Merck & Co.

Co-investorsJeito CapitalMRL Ventures FundSV Health Investors

FemTechHealthtechMedical DevicesRedwood City, US

Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)

BoardKen Haas(Director)Jonathan MacQuitty(Director)inMike Carusi(Director)inDoug Fisher(Director)

Co-investorsAmzak HealthEndeavour VisionFemHealth VenturesKaiser Permanente VenturesKluz VenturesLightstone Ventures+5 more

Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.

AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US

Aaron Hurst(Founder)in

Co-investorsVoyager CapitalAlly Bridge GroupAmed VenturesAscension VenturesCatalio Capital ManagementDelos Capital+2 more

Co-investorsCatalio Capital Management, LP

Co-investorsRA Capital

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

BiotechPhiladelphia, US

Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)

BoardTomas Kiselak(Director)

Co-investorsOUP (Osage University Partners)Pfizer Venture InvestmentsAgent CapitalLongwood FundOsage University PartnersPfizer Ventures+2 more

Bain Capital is a private equity investment firm with a Tokyo office that provides capital and strategic support to Japanese mid-market and large enterprises pursuing growth, restructuring, and business succession.

Enterprise SoftwareTokyo, JP

Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBain Capital Venture

Clinical-stage biotech using its RAPID chemoproteomics platform to drug challenging targets; acquired by Otsuka in 2024.

Boston, US

Co-investorsAvalon BioVenturesPfizer Venture InvestmentsRA Capital

Kailera develops obesity management medications, including GLP-1 and multi-agonist receptor peptides and small molecules, with a global development pipeline led by injectable and oral formulations of ribupatide.

BiotechHealthtechMedical Devices

Co-investorsAtlas VentureCatalio Capital Management, LP

BiotechRadnor, US

Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)

BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)

Co-investorsAvoro Capital AdvisorsCanaan PartnersConnecticut InnovationsSofinnova VenturesDomain AssociatesFlare Capital Partners+1 more

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).

BiotechHealthtechCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)ANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)

Co-investorsF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestPfizer Venture InvestmentsRho Ventures

NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.

BiotechHealthtechMedical Devices

Co-investorsEQT Life SciencesFrazier Life SciencesLSP (Life Sciences Partners)

Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.

Co-investorsAccess BiotechnologyLightstone VenturesPfizer Venture InvestmentsRA CapitalSV Health Investors

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)Mark Goldsmith(Director)

Co-investorsEcoR1 CapitalForesite CapitalSofinnova VenturesThe Column Group

Nuvalent is a biopharmaceutical company that uses chemistry and structure-based drug discovery to design small-molecule kinase inhibitors as precisely targeted cancer therapies.

BiotechHealthtechCambridge, US

Matthew Shair(Director)inHenry Pelish, PhD(Chief Scientific Officer)R. Porter James(Executive Officer, Director)inAlex Balcom(Executive Officer)inJames Porter, PhD(Chief Executive Officer)Alex Balcom, MBA, CPA(Chief Financial Officer)in

Co-investorsAvoro Capital Advisors

Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US

Sri Kosuri(Co-founder)inRamsey Homsany(Founder)in

Co-investorsAndreessen Horowitz+ND Capital8VCCarbon SiliconCatalio Capital Management, LPFifty Years+5 more

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Co-investorsAvoro Capital AdvisorsLightspeed Venture PartnersRA Capital

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsForesite CapitalKurma PartnersvenBio Partners

Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.

BiotechHayward, US

Kegan Schouwenburg(Executive Officer, Director)Roger M. Perlmutter(Executive Officer, Director)in

BoardJoshua Wolfe(Director)inDror Berman(Director)James Tananbaum(Director)Leon Chen(Director)

Co-investorsCisco InvestmentsForesite CapitalLux CapitalDimension Capital

Clinical-stage company developing novel therapies for orphan renal diseases.

Co-investorsPureos BioventuresSR One Capital Management

HealthtechStamford, US

Daniel S. Lynch(Executive Officer, Director)inSaqib Islam(Executive Officer, Director)Michael Greco(Executive Officer)

BoardStephen Squinto(Director)inDeval Patrick(Director)Carl L Gordon(Director)in

Co-investorsPfizer Venture InvestmentsOrbiMed

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSamsara BioCapitalThe Column GroupCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.

BiotechHealthtechMental Health

Co-investorsThird Rock VenturesGV (Google Ventures)

Co-investorsSofinnova Ventures

Bain Capital Tech Opportunities is a technology-focused investment firm that provides growth capital, along with strategic and operational support, to entrepreneurs and management teams during expansion phases.

Enterprise SoftwareFintechSaaS

Co-investorsBain Capital Double Impact Fund LPBain Capital Venture

Co-investorsAtlas Venture

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets.

BiotechHealthtech

HealthtechCampbell, US

Michael Buck(Executive Officer, Director)

BoardFarhad Khosravi(Director)Charles Chon(Director)Daniel Davis(Director)John Buckley(Director)

Co-investorsAlly Bridge GroupAscension VenturesInnovatus Capital Partners

BiotechSan Diego, US

Brittany Bradrick(Executive Officer)Anne Sandan(Executive Officer)Elizabeth Bui(Executive Officer)Steve White(Executive Officer)Howard Foyt(Executive Officer)inKevin D'Amour(Executive Officer)

Co-investorsRA CapitalSanderling VenturesThe Vertical GroupRed Tree Venture